Skip to main content
. 2020 Jun 8;123(5):785–792. doi: 10.1038/s41416-020-0925-4

Fig. 4. Relationship between ER pathway activity score and ER IHC expression in patients with and without a recurrence in the Nijmegen clinical cohort.

Fig. 4

a ER pathway activity scores in patients with and without a recurrence, according to stage and histology. b ER IHC expression in patients with and without a recurrence, according to the stage and histology. c ER pathway activity score in patients with and without a recurrence, according to ER IHC expression groups. Dots represent samples from individual patients, five patients with residual disease were excluded from this analysis (USC: n = 4, EEC stage II–IV: n = 1). EEC endometrioid-type endometrial cancer, USC uterine serous cancer. *P < 0.05.